Climb Bio kompaniyasidagi eng so‘nggi ish o‘rinlari

Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody therapies for immune-mediated diseases. Its clinical pipeline includes budoprutug (CLYM116), with research focused on conditions such as primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, and IgA nephropathy. The company is also exploring CD19-directed treatments for diseases where patients have significant unmet needs. Climb Bio’s work spans drug development and clinical trials, with a patient-centered approach to evaluating potential therapies.